Finance

Lists
SYRE:NASDAQ
Spyre Therapeutics Inc
$90.24
-0.62%
(-0.56) 1D
Sep 15, 2:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SYRE...
Open
$90.82
High
$90.82
Low
$88.47
Mkt. cap
7.96B
Avg. vol.
1.03M
Volume
359.69K
52-wk high
$110.18
52-wk low
$14.50
EPS
-$2.32
Beta
2.99
Shares outstanding
88.17M
No. of employees
125
Open
$90.82
High
$90.82
Low
$88.47
Mkt. cap
7.96B
Avg. vol.
1.03M
Volume
359.69K
52-wk high
$110.18
52-wk low
$14.50
EPS
-$2.32
Beta
2.99
Shares outstanding
88.17M
No. of employees
125
News stories
From web sources and news partners
About Spyre Therapeutics Inc
CEO-
Employees125
FoundedJan 1, 2013
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitespyre.com
Analyst ratings
Based on 13 analysts giving stock ratings to SYRE in the past 3 months
Strong buy
Buy
12
Hold
1
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for SYRE in the last 3 months.
Highest
Current $90.24
$130.00 (+44.06%)
Average
$122.73 (+36.00%)
Lowest
$115.00 (+27.44%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
$123.00
+36.3%
09/09/2026
Akash Tewari
Jefferies
Buy
Maintained
$126.00
+39.6%
09/09/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$128.00
+41.8%
09/10/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$116.00
+28.5%
09/08/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$130.00
+44.1%
08/26/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$121.00
+34.1%
08/26/2026
Julian Harrison
BTIG
Buy
Reiterated
$121.00
+34.1%
08/26/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$115.00
+27.4%
08/25/2026
David Hoang
Deutsche Bank
Buy
Maintained
$127.00
+40.7%
08/26/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$123.00
+36.3%
08/13/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$120.00
+33%
08/05/2026
Andy Chen
Wolfe Research
Hold
Downgraded
-
-
07/28/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$120.00
+33%
07/13/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
06/23/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
06/03/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$115.00
+27.4%
05/06/2026
Samantha Semenkow
Citi
Buy
Reiterated
$97.00
+7.5%
05/06/2026
Martin Auster
Raymond James
Buy
Initiated
$80.00
-11.3%
04/10/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.36 / -$0.75
+51.78%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
45.25M
44.64M
60.41M
65.50M
Cost of revenue
45.25M
44.64M
60.41M
65.50M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.64M
12.53M
15.23M
16.14M
Operating expense
11.64M
12.53M
15.23M
16.14M
Total operating expenses
56.89M
57.17M
75.64M
81.64M
Operating income
-56.89M
-57.17M
-75.64M
-81.64M
Other non operating income
40.33M
-12.50M
-30.36M
-4.61M
EBT including unusual items
-11.18M
-62.53M
-69.00M
-36.20M
EBT excluding unusual items
-11.18M
-62.53M
-99.00M
-76.20M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.18M
-62.53M
-69.00M
-36.20M
Net profit margin
-
-
-
-
Earnings per share
-0.15
-0.74
-0.74
-0.36
Interest and investment income
5.38M
7.14M
7.00M
10.05M
Interest expense
-
-
-
-
Net interest expenses
5.38M
7.14M
7.00M
10.05M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-30.00M
-40.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps